Annual report
8086.TEDINET S100TUDK
Period2023-04-01 → 2024-03-31
Filed2024-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 154
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥586.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥545.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥494.8bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥455.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥442.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥22.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥17.7bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥19.5bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥15.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥27.6bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥26.3bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥23.4bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥19.2bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥16.8bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥11.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.5bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.2bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥12.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥12.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥5.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥1.11T | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.03T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥930.3bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥854.4bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥831.9bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥840.0bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥785.2bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥269.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥242.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥199.9bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥174.1bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥161.2bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥99.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥89.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥96.6bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥84.7bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥85.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥90.2bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥72.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥68.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥66.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥37.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥87.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥71.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥78.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥45.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥58.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥22.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥43.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥10.3bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥22.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.6bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥68.12 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥28.05 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.5 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.12 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-75.3 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥60.35 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.85 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥77.42 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,426.56 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,265 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,135.76 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥987.3 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥912.24 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 21.0% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 18.8% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 17.9% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.3% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | -7.9% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 38,117 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 38,770 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 36,259 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 35,251 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 32,786 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥368.3bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥349.7bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥331.2bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥334.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥340.8bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥5.8bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥3.3bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥9.7bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥8.7bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥17.5bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.5bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥10.4bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥11.6bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥6.9bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥8.7bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥10.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥9.7bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥16.4bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥808.6bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥764.9bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥727.0bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥695.1bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥666.1bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥621.1bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥583.3bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥187.5bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥181.6bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥179.7bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥173.7bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥157.7bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥23.3bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥7.6bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥42.1 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.47 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.87 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.72 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-100.66 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥37.3 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥47.38 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥61.82 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥25 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥22 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥27 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥13.5 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,149.68 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,113.64 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,102.07 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,065.15 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥966.84 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 23.2% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.7% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.7% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.0% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.7% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.9% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -10.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 171,459,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4,388 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 4,390 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 4,252 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 4,150 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 4,060 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 103
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥739m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥407m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2024-03-31 | 119 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥5.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥816m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥4.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥234.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥80m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥7.8bn |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥5.1bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥71.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥71.4bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | −¥142.0bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥27.0bn |
| Medical Treatment Relatedreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥48.7bn |
| Medical Treatment Relatedreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥29.1bn |
| Medical Treatment Relatedreportable segment | employees | at 2024-03-31 | 26771 pure |
| Medical Treatment Relatedreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥459.3bn |
| Medical Treatment Relatedreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥453.6bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥5.7bn |
| Medical Treatment Relatedreportable segment | segment assets | at 2024-03-31 | ¥663.6bn |
| Medical Treatment Relatedreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥42.3bn |
| Medicine Relatedreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥31.9bn |
| Medicine Relatedreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥15.0bn |
| Medicine Relatedreportable segment | employees | at 2024-03-31 | 7630 pure |
| Medicine Relatedreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥129.6bn |
| Medicine Relatedreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥74.3bn |
| Medicine Relatedreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥55.3bn |
| Medicine Relatedreportable segment | segment assets | at 2024-03-31 | ¥243.2bn |
| Medicine Relatedreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥4.4bn |
| Pharma Packagingreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥14.5bn |
| Pharma Packagingreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥6.4bn |
| Pharma Packagingreportable segment | employees | at 2024-03-31 | 2781 pure |
| Pharma Packagingreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥64.3bn |
| Pharma Packagingreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥58.0bn |
| Pharma Packagingreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥6.3bn |
| Pharma Packagingreportable segment | segment assets | at 2024-03-31 | ¥110.7bn |
| Pharma Packagingreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥2.5bn |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥95.1bn |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥50.5bn |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥653.2bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥586.0bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥67.2bn |
| —segment total | segment assets | at 2024-03-31 | ¥1.02T |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥49.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥95.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥50.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥658.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥586.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥71.4bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥1.25T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥49.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-04-01 → 2023-03-31 | ¥365m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥339m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥4.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥752m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥3.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥201.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥257m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥14.0bn |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥4.6bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥38.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥38.3bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | −¥111.7bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥29.5bn |
| Medical Treatment Relatedreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥49.1bn |
| Medical Treatment Relatedreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥22.5bn |
| Medical Treatment Relatedreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥426.1bn |
| Medical Treatment Relatedreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥420.0bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥6.1bn |
| Medical Treatment Relatedreportable segment | segment assets | at 2023-03-31 | ¥618.6bn |
| Medical Treatment Relatedreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥38.6bn |
| Medicine Relatedreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥23.5bn |
| Medicine Relatedreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥13.4bn |
| Medicine Relatedreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥95.2bn |
| Medicine Relatedreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥72.7bn |
| Medicine Relatedreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥22.5bn |
| Medicine Relatedreportable segment | segment assets | at 2023-03-31 | ¥221.6bn |
| Medicine Relatedreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥5.6bn |
| Pharma Packagingreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥15.7bn |
| Pharma Packagingreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥5.5bn |
| Pharma Packagingreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥57.7bn |
| Pharma Packagingreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥51.8bn |
| Pharma Packagingreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥6.0bn |
| Pharma Packagingreportable segment | segment assets | at 2023-03-31 | ¥97.2bn |
| Pharma Packagingreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.7bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥88.2bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥41.3bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥579.0bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥544.4bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥34.6bn |
| —segment total | segment assets | at 2023-03-31 | ¥937.4bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥47.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥88.6bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥41.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥583.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥545.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥38.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥1.14T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥47.2bn |
| Medical Treatment Relatedreportable segment | employees | at 2024-03-31 | 3384 pure |
| Medicine Relatedreportable segment | employees | at 2024-03-31 | 27 pure |
| Pharma Packagingreportable segment | employees | at 2024-03-31 | 161 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,089
| Item | Context | Value | Unit |
|---|---|---|---|
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.716 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.734 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | 0.591 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.000 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.125 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.679 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.740 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | 0.774 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.092 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 1.125 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.351 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.692 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row3Member | 0.444 | |
| Ratio of female employees in managerial positions metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | 0.233 | |
| All employees ratio of male employees taking childcare leave metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | 0.500 | |
| All employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | 0.813 | |
| Regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | 0.840 | |
| Non regular employees differences in wages between male and female employees metrics of consolidated subsidiaries | CurrentYearInstant_Row4Member | 0.274 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 55.0 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 48.3 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 80.0 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row2Member | 70.1 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 10.0 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row3Member | 5.5 | |
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | 15.0 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row4Member | 22.5 | |
| Research and development expenses research and development activities | CurrentYearDuration | 20846000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 11260000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02688-000MedicineRelatedReportableSegmentsMember | 9585000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 95342000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 42869000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02688-000MedicineRelatedReportableSegmentsMember | 31655000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02688-000PharmaPackagingReportableSegmentMember | 14453000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_CorporateSharedMember | 6364000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 95342000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 171459479 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 171459479 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 171459479 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 171459479 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 44 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 29 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 454 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 226 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 76 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 61987 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 62816 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 380041 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |